Stockscreener 앱 받기
2.74
1.48%
0.04
시간 외 거래:
2.74
Mannkind Corp 주식(MNKD)의 최신 뉴스
Why MannKind Corporation (MNKD) is One of the Best Stocks Under $5 With Huge Upside Potential - Insider Monkey
5 Stocks Under $5 with Huge Upside Potential - Insider Monkey
MannKind (NASDAQ:MNKD) Upgraded at Zacks Research - MarketBeat
MNKD Should I Buy - Intellectia AI
MNKD Stock Price, Quote & Chart | MANNKIND CORP (NASDAQ:MNKD) - ChartMill
Truist Securities Touts MannKind Corporation (MNKD) Prospects on Tyvaso Franchise Development - Insider Monkey
5 Best Healthcare Penny Stocks to Buy According to Hedge Funds - Insider Monkey
MNKD Maintains Rating by Mizuho -- Price Target Lowered to $8.00 - GuruFocus
Leerink reiterates Outperform on MannKind stock, sees overreaction - Investing.com
Leerink reiterates Outperform on MannKind stock, sees overreaction By Investing.com - Investing.com UK
Risk Check: Is MannKind Corporation in a bullish channel2026 Snapshot & Weekly High Return Opportunities - baoquankhu1.vn
Non Tuberculous Mycobacterial Infections Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Insmed, AN2 Therapeutics, Mannkind Corp., Spero Therapeutics, Savara Pharmaceuticals - Barchart.com
MannKind (NASDAQ: MNKD) details 2026 virtual meeting, board elections and pay vote - Stock Titan
MannKind CEO and CFO to speak at two Miami healthcare events - Stock Titan
Q4 2025 MannKind Corp Earnings Call Transcript - GuruFocus
Q2 2025 MannKind Corp Earnings Call Transcript - GuruFocus
Truist reiterates MannKind stock rating on partner trial data By Investing.com - Investing.com India
Truist reiterates MannKind stock rating on partner trial data - Investing.com
Is MannKind Corporation (MNKD) One of the Popular Penny Stocks on Robinhood to Buy? - Insider Monkey
Vanguard disaggregates holdings; MannKind (MNKD) shows 0 shares in 13G/A - Stock Titan
MannKind (MNKD) EVP receives new performance RSU and option awards - Stock Titan
MannKind (MNKD) awards performance RSUs and stock options to officer - Stock Titan
Setup Watch: Is now the right time to enter MannKind CorporationTrend Reversal & Smart Allocation Stock Reports - baoquankhu1.vn
How The MannKind (MNKD) Story Is Shifting As Tyvaso Risks Meet Afrezza And Furoscix Potential - Yahoo Finance
Chart Watch: Whats the beta of MannKind Corporation stockMarket Risk Summary & Daily Risk Controlled Trade Plans - baoquankhu1.vn
MannKind Corp. Hits Day Low of $3.29 Amid Price Pressure - Markets Mojo
MannKind Corp stock hits new 52-week low on NASDAQ amid analyst downgrades and earnings miss - AD HOC NEWS
MannKind (NASDAQ:MNKD) Hits New 12-Month LowHere's What Happened - MarketBeat
MannKind stock slips despite FDA clearing pediatric use of heart failure drug — what’s spooking investors? - MSN
A Key "Master" Protein That Declines by Half After Age 40. One Company Found a Way to Restore It. - Benzinga
MannKind: Strategic Uncertainty Follows United Therapeutics' Pivot (Rating Downgrade) - Seeking Alpha
MannKind Corp. Stock Plummets to New 52-Week Low of $3.29 - Markets Mojo
Portfolio Update: Is MannKind Corporation in a bullish channel2026 Selloffs & Scalable Portfolio Growth Ideas - baoquankhu1.vn
(MNKD.O) | Stock Price & Latest News - Reuters
MannKind Corp Stock (ISIN: US5638651064) Faces Pressure Amid Biotech Selloff and Analyst Cuts - AD HOC NEWS
MannKind (NASDAQ:MNKD) Rating Lowered to Strong Sell at Zacks Research - MarketBeat
Why MannKind Needs Your Attention - RTTNews
MannKind at Barclays Healthcare Conference: Strategic Growth and Innovation - Investing.com
MannKind at Leerink Global Healthcare: Expanding Horizons in Pharma - Investing.com
MannKind (NASDAQ:MNKD) CEO Buys $259,000.00 in Stock - MarketBeat
MannKind (NASDAQ: MNKD) CEO purchases 100,000 shares in market trade - Stock Titan
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026 - The Manila Times
MannKind presents Afrezza data at diabetes conference - Investing.com
MannKind Corporation to Present Data on Inhaled Insulin Afrezza at ATTD 2026 Conference - Quiver Quantitative
Afrezza needle-free insulin for kids heads for FDA decision May 29, 2026 - Stock Titan
How The MannKind (MNKD) Investment Story Is Shifting With New Risks And 2026 Catalysts - Yahoo Finance
2.53%
2.69%
자본화:
|
볼륨(24시간):